BTIG Research initiated coverage on AC Immune with a new price target
$ACIU
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research initiated coverage of AC Immune with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/31/2024 | $8.00 | Buy | BTIG Research |
| 12/20/2021 | $17.00 → $15.00 | Outperform | SVB Leerink |
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
6-K - AC Immune SA (0001651625) (Filer)
BTIG Research initiated coverage of AC Immune with a rating of Buy and set a new price target of $8.00
SVB Leerink reiterated coverage of AC Immune with a rating of Outperform and set a new price target of $15.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of AC Immune with a rating of Buy and set a new price target of $16.00 from $11.00 previously
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseasesACI-19764 is an important addition to AC Immune's growing small molecule pipelinePhase 1 results in healthy volunteers are expected in H2 2026 Lausanne, Switzerland, February 24, 2026 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that the first participant has been dosed in a Phase
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson's diseaseClear safety profile with no clinically relevant safety issues reportedTargets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessmentsUnderlines potential and importance of active immunotherapies in precision medicine for neurodegenerative diseasesAC Immune to host webcast and conference call today at 9:00am ET / 15:00 CET details below Lausanne, Switzerlan
AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. The fireside chat will take place on November 18, 2025, at 4:30 AM (ET) / 9:30 AM (GMT). A webcast of the fireside chat will be available on the Events Page of AC Immune's website. A replay will be archived in the same location. Please con
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalitiesIncludes immunotherapies and small molecule drugs targeting intracellular proteinopathiesLeadership in groundbreaking early-stage clinical trials reinforces Company's competencies Lausanne, Switzerland, October 28, 2025 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in d
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Off
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will join the Company on October 1st, as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, currently Chief Medical Officer, will leave at the end of September to pursue a new role. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "It is with great pleasure that we welcome Dr Mendonça to our
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson's diseaseClear safety profile with no clinically relevant safety issues reportedTargets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessmentsUnderlines potential and importance of active immunotherapies in precision medicine for neurodegenerative diseasesAC Immune to host webcast and conference call today at 9:00am ET / 15:00 CET details below Lausanne, Switzerlan
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)
AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further develop its SAIT and monoclonal antibody for cardiovascular disease and for Huntington's disease, respectively VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)
SC 13G/A - AC Immune SA (0001651625) (Subject)